ENDOCRINE

1. Non functioning pituitary mass (apr 2012)

2. Neuro psychiatric manifestations of endocrine disorders (apr 2010)
3. Biochemical defect in and mode of inheritance of erythropoietic porphyria (apr 2010)
4. Early diagnosis of diabetic nephropathy (nov 2009)
5. Exenatide (nov 2009)
6. Prognostic scoring system in wilsons disease (nov 2009)
7. Thyrotoxicosis management ( apr/may 2009)
8. Diagnosis of diabetes mellitus ( apr/may 2009)
9. Insulin resistance (apr/may 2009)
10. Wilsons disease (apr/may 2009)
11. Cushing’s syndrome ( apr 2012)
12. Gynecomastia ( apr 2012)
13. Gestational diabetes ( apr 2011)
14. Hypoglycaemia
15. Management of diabetic ketoacidosis ( jun 2003)
16. Hypothyroidism ( jun 2008,oct13)
17. SIADH ( nov 2006, jan 99)
18. Hemochromatosis ( nov 2006, 07, may 2005)
19. Hyperosmolar nonketotic coma ( nov 2006)
20. Turner’s syndrome ( may 2007)
21. Adrenal crisis ( nov 2007)
22. Insulin sensitizers ( may 2007)
23. Multiple endocrine neoplasia ( may 2007)
24. Gastrinoma triangle and its significance ( nov 09)
25. Microvascular complications of diabetes ( nov 2007)
26. Oral hypoglycemic drugs ( nov 2007)
27. Second generation sulphonyl ureas ( mar 2004)
28. Assessment of thyroid dysfunction ( sep 2003)
29. Short notes on serum triglycerides ( sep 2003)
30. Insulinoma (mar 2003)
31. HDL cholesterol ( mar 2003)
32. Regulation of thyroid harmone synthesis. How do you investigate hypothyroidism
( mar 2003)
33. Thyroid function tests ( may 2007)
34. Newer insulins ( may 2007)
35. Fatty liver ( may 2007)
36. Hypercalcemia ( nov 2006, may 2005, oct13)
37. Thiazolidenediones (may 2005, mar 03)
38. Bisphosphonates ( may 2005)
39. Short notes on ACTH stimulation test ( sep 2002)
40. Notes on T3 toxicosis (jun 99)
41. Lipid lower agents ( jun 99)
42. Enumerate merits and demerits of different methods used to assess control of DM
( jan 99)
43. Discuss merits of various thyroid function tests in recognition of thyroid disorders.
Write principles of management of hyperthyroidism. (aug 98)
44. prolactin ( sep 96)
45. what are lipids and give the lipid profile of a healthy adult person. Describe the
causes and manifestations of hyperlipidemia. How do you manage ( jul 94)
46. calcitonin ( jan 95)
47. prevention of type2 DM ( sep 03)
48. clinical features and treatment of primary and secondary hyperparathyroidism
(mar03, jan 95)
49. Acromegaly ( mar 03)
50. discuss the pathology and implication and management of post prandial
Hyperglycemia (sep 2002)
51. somogys effect ( may 2000)
52. diabetic amyotrophy (sep 96)
53. dawn phenomenon ( jan 95)
54. Acarbose ( sep 2004)
55. syndrome X ( sep 04)
56. sibutamine ( sep 02)
57. discuss the etiology, clinical manifestations, diagnosis $ management of
Osteoporosis. ( jan 99)
58. thyrotoxic crisis ( may 05, sep 96)
59. insulin regimens ( sep 04)
60. monitoring the level of glycemic control (mar 04)
61. describe the pathophysiology of diabetic neuropathy. Outline the prevention of
diabetic foot complications. (mar 03)
62. fasting hypoglycaemia ( may 00)
63. feminisation in the male ( feb 98)
64. galactorrhoea ( sep 97)
65. auto immune hepatitis ( nov 09)
66. non ulcer dyspepsia (nov 09)
67. sibutramine
68. orlistat
69. insulin sensation.
70. endocrine emergencies (nov 09)
71. myxedema coma
72. spontaneous hypoglycaemia
73. subclinical hypothyroidism
74. biochemical aberrations in and mode of inheritance of porphyria cutaneous
Tarda ( nov 09)
75. chromographins ( nov 09)
76. somatostatin (jun 99)
77. microalbuminuria (aug 98)
78. marfans syndrome ( mar 04)
79. adrenal crisis ( sep 02)
80. dexamethasone suppression test (nov 09)
81. wilsons disease (may 09)
82. clinical features of carcinoid syndrome (nov 09)
83. Current concepts in management of dyslipidemia (nov 09)
84. discuss ukpds and its clinical implications (sep 03)
85. hyperuricemia (oct13)
86. andropause(oct12)
87. autoimmune thyroiditis(oct12)
88. impaired glucose tolerance (oct12)
89.hypoadrenalism in india – causes , detection management. (oct13)
90. hypophosphatemia (apr13)
91. autoimmune hypothyroidism(apr13)
92. contra indications to androgens (apr13)
93. somatostatinomas (oct12)
94. dyslipidemia in DM (oct12)
95.malnutrition related DM (oct12)
 RESPIRATORY SYSTEM

1. Pulmonary function test. (nov 2012, sep 03,apr13)

2. Obstructive sleep apnoea. (nov 2012, apr 11, may 06,oct12)
3. Hemoptysis and approach to a patient with hemoptysis. (nov 2012)
4. Acute respiratory failure. (apr 2012)
5. Enumerate causes, clinical features, principles of Management of acute
respiratory distress syndrome. (apr 10, jan99, may 05, nov 08)
6. Leukotriene antagonists. (nov 09)
7. Sleep apnoea syndrome ( apr/may 09, sep 03,96, feb 98)
8. Ventilator associated pneumonia. ( apr/may 09)
9. Chronic persistent bronchial asthma (apr/may 09)
10.Solitary pulmonary nodule ( nov 11, jun 08,apr13)
11.Newer drugs in the management of bronchial asthma. (nov 11)
12.Cough mechanism, diagnosis, management
13.Pneumoconiosis (nov 06)
14.Management of COPD. (may 07, 05)
15.Diagnosis and management of pneumonia. (sep02, may 05,07)
16.Fiber optic bronchoscopy (nov07, may05, sep 03)
17.Environmental lung disease (nov 07)
18.Percussion of lung (nov 07)
19.Aspiration pneumonia (nov 07)
20.Pathophysiology of asthma (nov 06)
21.Bronchoalveolar lavage (nov 06)
22.Describe the ventilator function of lung &its various abnormalities (jun 99)
23.Write the blood supply, venous drainage, & lymphatic drainage of lungs.
What are the applied uses of the continuous knowledge. (feb 98)
24.Unilateral pulmonary function tests
25.Describe diagnosis & management of interstitial pulmonary fibrosis
( may 05)
26.Newer drugs in the management of bronchial asthma (mar04, nov 08)
27.O2 therapy& non invasive ventilation in COPD and chronic respiratory
failure. (sep 03)
28.Essay on interstitial lung diseases (feb 08, sep 04)
29.Short notes on broncho pulmonary aspergillosis (jan 95)
30.Define COR PULMONALE. Describe the types, causes, clinical features,
and management of chronic COR PULMONALE. (jul 94, nov 08)
31.Primary pulmonary hypertension(jan 95)
32.Enumerate etiology, clinical features, and management of
pneumothorax(aug 98)
33.Describe the causes, complications, prevention,and treatment of pulmonary
thromboembolism. (sep 02)
34.Pulmonary alveolar microlithiasis (mar 03)
35.Write in detail mechanical ventilator. Write the indications of various
ventilator modes in clinical practice (mar 03, 04)
36.Non invasive ventilation (apr 11)
37.Tension pneumothorax (nov 10)
38.Acute severe asthma (nov 10)
39. Alpha-1 anti trypsin deficiency (sep 96)
40. Leukotriene antagonists (nov 09)
41.Brittle asthma (oct12)
42.Oxygen dissociation curve. And its determinants (oct13)
43.Refractory asthma (apr13)
 NUTRITON
1. Anorexia nervosa((apr 12)
2. Enteral nutrition (apr 12)
3. Trace elements (apr 12)
4. management of obesity (apr/may 09, nov 11)
5. Warnicke korsakoff (nov 09)
6. Osteoporosis (nov 08,10)
7. Tetany ( nov 08)
8. Parenteral nutrition (nov 11, apr 11)
9. Pathological consequences of obesity (nov 10)
10. Pellagra (nov 11)
11. Physiology of hunger. Pathophysiology of obesity (sep 03,apr13)
12. Retinoic acid (sep 02)
13.Vitamin B12 (apr13)
14.Vitamin D and calcium homeostasis (oct13)
15.Magnesium in health and diseases (oct13)
16.Clinical evaluation and management of recently diagnosed obese diabetic
(oct13)
17.B12 defeciency in india. Diagnosis and management (oct13)
18.VitaminD deficiency in india (oct13)
19.Physiology of weight regulation (oct12)
20.Beri-beri (oct12)
21.
 GENETICS
1. Methods of analysis of human DNA ( apr 12)
2. Treatment and prevetion of genetic diseases (apr 12)
3. X- linked muscular dystrophies (apr 10)
4. Cloning (apr 09)
5. Stem cell transplantation ( apr 09,oct12)
6. Describe the principles of gene therapy & its present status in
treatment of diseases (aug 98)
7. Genetic councelling ( sep 04, nov 08)
8. Multifactorial genetic disorder (nov 11)
9. Gene therapy (nov 11)
10. Human genome project. Its implications in clinical medicine. (sep 04)
 CARDIOVASCULAR SYSTEM
1. Malignant hypertension and its management (apr 10)
2. Anagrelide (apr 10)
3. Genetically determined arrhythmia syndromes (apr 10)
4. Conduction system of heart and its theurapeutic applications (apr 10, mar 04,
sep 03, jan 99)
5. Neutritional cardiovascular illness (nov 09)
6. Wide QRS tachycardia (may 09)
7. Eisenmenger syndrome (may 09)
8. Beta blocker as first drug for HTN (may 09)
9. Primary pulmonary hypertension (nov 11)
10.Anti arrhythmic drugs (nov11)
11.Anti arrhythmic drugs for atrial fibrillations (apr 12)
12.Drug eluting stunts (apr 11)
13. Refractiory heart failure (jun 08, nov 07)
14.Long QT syndrome (jun 08)
15.Syndrome X (may 07)
16.Beta blockers (may 07, sep 04)
17.Unstable angina (nov 09, apr 10)
18.Hepato-jugular reflex (nov 07, mar 04)
19.WPW syndrome ( nov 07)
20. Atrial natriuretic peptide ( mar 04)
21.Amiodarone ( nov 06)
22.Indications of echocardiography by signs and symptoms ( may 06)
23.Role of endothelin in HTN ( may 05)
24.Angiotensin receptor antagonists ( sep 04)
25.Describe the anatomy of coronary arteries and its applications in disease
management ( aug 98)
26.Management of endocarditis ( may 07)
27.Pharmacological stunt testing ( may 05)
28.Describe pathophysiology and current trends in management of heart failure
(may 05, aug 98, feb 98)
29.Etiology and management of atrial fibrillations (mar 04)
30.Harmone replacement therapy in CAD ( sep 03)
31.Non ST elevation ACUTE CORONARY SYNDROMES ( sep 03)
32.What are the effects of physiology and pharmacologic intervention on the
intensity of heart murmur sounds ( may 00)
33.Prevention and treatment of atherosclerosis (may 00)
34.Describe the role of dynamic ausculatation in cardio vascular diagnosis ( jan
99)
35.Discuss the etiopathogenesis, pathology, clinical features and diagnosis of
restrictive cardiomyopathy and its management ( sep 96)
36.Enumerate the etiology of pericarditis, describe the clinical features,
complications, diagnosis and treatment of pericarditis with effusion. (jan 95)
37.Describe the cause, clinical features of systemic hypertension and scheme of
management of HTN. ( jul 94)
38.Short notes on JVP( jul 94)
39.Short notes on carvedilol (sep 02)
40.Short notes on potassium channel activators( aug 98)
41.LMWH in CAD ( sep 04)
42.Diet in cardiovascular diseases (jun 99)
43.Discuss pathogenesis of renovascular HTN. Which investigations are useful
in its diagnosis ( mar 04)
44. Coronary stunts ( may 06)
45.Radio-frequency radiocatheter ablation (may 04)
46.Framingham criteria for diagnosis of congestive cardiac failure ( sep 04)
47.Report of JNC 8 on HTN (coming soon)
48.ECG diagnosis of LVH( sep 03)
49.Role of cardiac troponins in acute coronary syndrome( sep ..)
50.Describe the etiology, diagnosis, and management of diastolic heart failure (
may00)
51.Importance of pulse in cardiovascular diagnosis (jun 99)
52.Classify cardiac arrhythmic drugs. Write the clinical pharmacology and
toxicity ( sep 97)
53.Jone’s criteria for diagnosis of rheumatic fever ( may 05)
54.Nutritional cardiovascular illness ( nov 08)
55.Brady arrhythmias (nov 08)
56.CORPULMONALE ( nov 08)
57.Acute coronary syndrome ( nov 08)
58.Framinghams criteria for heart failure ( nov 09)
59.Natriuretic harmone ( may 05)
60. Recent concepts in the management of dislipidemias ( nov 09)
61.Abciximab (nov 09)
62.Secondary HTN ( nov 08)
63.Blood supply of heart and its clinical implication ( nov 11)
64.Cardiac tamponade(nov 10)
65.Thrombolysis in acute MI
66.IHD and cardiomyocyte regeneration (apr13)
67.Hypertrophic cardiomyopathy(apr13)
68.Thrombolysis in practice (oct13)
69.Refractory hypertension-causes, evaluation and management(oct13)
70.Tachyarrythmias- diagnosis, evaluation and management (oct13)
71.Atherosclerosis – pathogenesis and risk factors (oct13)
72.Genetics in Hypertrophic cardio myopathy (oct12)
73.Management of HTN in elderly (oct12)
74.Management of pulmonary HTN(oct12)
75.Endomyocardial fibrosis(oct12)
 GASTROINTESTINAL SYSTEM
1. Approach to a patient with jaundice (apr 12,nov08,oct13)
2. Non alcoholic steatohepatitis (apr 10)
3. Dermatological manifestations of gastro intestinal disorders (apr 10)
4. Management of inflammatory bowel disease ( apr 10)
5. Exocrine pancreatic function tests ( apr 10)
6. Clinical features of carcinoid syndrome ( nov 09)
7. Irritable bowel syndrome ( may 09, nov 09, jun 99, )
8. Non cirrhotic portal fibrosis ( may 09)
9. GERD (may 09,07, sep 03, aug 98)
10.Hepato-renal syndrome (may 09)
11.Medical acute abdomen ( nov 11, jun 08, feb 98)
12.Chronic pancreatitis ( nov11, nov 06)
13.Serology of viral hepatitis (nov 11, jan 99, jun 08)
14.Serological markers of autoimmune hepatitis (apr 12, sep 97)
15.Approach to lower GI bleed( apr 12)
16.Upper GI bleed ( nov 06, jan 99)
17.PPI (nov 06, mar 04, may00)
18.Helicobacter pylori (nov 06, sep 04, nov 08, oct12)
19.Primary biliary cirrhosis ( nov 06)
20.Chronic hepatitis ( nov07, sep 04)
21.Anatomy of portal system and causes, clinical features, complications, and
management of portal hypertension (mar04, 07, jul 94,apr13)
22.MR cholangio pancreatography (mar 03)
23.Fatty liver ( may 07)
24.ERCP (may 05)
25.Prokinetic drugs ( sep 04, 03)
26.Physiology of gastric acid production (may 05)
27.Describe the gastric physiology related to peptic ulcer ( jun 99, ma 04)
28.What are the GIT enzymes acting on protein digestion and absorption. What
are the clinical effects of enzyme deficiency ( sep 97)
29.Discuss the pathogenesis, pathology, and diagnosis of chronic active
hepatitis ( sep 96)
30.Gastrin (jul 94)
31.Serological course of acute hepatitis A and B. (may 05)
32.ZOLLINGER-ELLISON syndrome (jan 95)
33.Hepatitis virus (jul 94)
34.Risk of endoscopic procedure (mar 04)
35.Refractory hepatitis (sep 03, nov 08)
36.SAAG (jun 99)
37.Hepatitis C treatment (may 06)
38.Cholestasis (may 05)
39.Discuss therapy of chronic viral hepatitis ( may 05)
40.Variceal bleeding ( sep 04)
41.Whipple disease (sep 02)
42.Sub acute hepatitis failure ( jan 99)
43.Drug induced liver diseases (aug 98)
44.Role of usg in diagnosis of jaundice (aug 98)
45. Strategies in acute abdomen (feb 98)
46.Discuss the etiopathogenesis, clinical features and management of fulminant
hepatic failure ( sep 96)
47.Spontaneous bacterial peritonitis (mar 04, sep 04)
48.Malabsorption of tropics (may 04)
49.Tropical sprue ( may 05, 04)
50.Describe diagnosis, complications and management of amoebic liver abscess
(mar 04)
51.Discuss the etiopathogenesis, clinical features, diagnosis and management f
post infection malabsorption (sep 96)
52. Upper GI endoscopy (nov 08)
53. Discuss bilirubian metabolism (nov 11, oct13)
54.Jaundice during pregnancy ( apr 11)
55.Gastrinoma, its diagnosis and its significance (nov09)
56.Approach to chronic constipation
57.Hepatojugular reflux ( nov 07)
58.Evaluation of spleen ( may 06)
59.Dysphagia (nov 07)
60.Describe the causes, clinical features, investigations, and treatment of small
bowel disease (sep 02)
61.Acute pancreatitis. Diagnosis and management(oct13)
62.Alcoholic liver disease (apr13)
63.Tropical pancreatitis(apr13)
64.Approach to malabsorption (oct12)
65.Management of recurrent variceal bleed (oct13)
66.Investigations in cholestatic jaundice (oct12)
 RENAL SYSTEM
1. Hyponatremia ( apr 12)
2. Approach to a patient with proteinuria ( apr 12)
3. Alport’s syndrome ( apr 10)
4. Pathogenesis of renal osteodystrophy ( apr 10)
5. Uninhibited bladder ( apr 10)
6. Urinary indices in acute renal failure ( may 09)
7. Mechanism of immune mediated glomerular injury ( nov 11)
8. Micro-albuminuria (apr 11, mar 04)
9. Reno-vascular hypertension (apr 11)
10.Medical renal diseases (jun 08)
11.UTI ( jun 08,oct13)
12.Renal tubular acidosis ( nov 06, sep 03, jan 95)
13.Nephrotic syndrome ( may 07)
14.Lupus nephritis ( may 07)
15.Renal osteodystrophy ( nov 07)
16.Describe renal tubular functions. Write etiopathogenesis, clinical features of
RTA ( mar 04)
17.Short notes on functional urinary sodium excretion ( sep 03)
18.Proteinuria mechanism (may 06)
19. Uremic toxins (sep 04)
20.Haemolytic uremic syndrome ( may 05)
21.Renal failure indices (jun 99)
22.Immunological basis of glomerular injury ( sep 04, jan 99)
23.Hemodialysis Vs peritoneal dialysis ( may 06)
24.Acute tubular necrosis ( may 05)
25.Prevention in progress of CKD ( sep 04, 10)
26. Microproteinuria ( jan 95)
27.Diagnostic indices in pre-renal vs intrinsic renal , acute renal failure ( mar
04)
28.Renal tubular functions tests ( feb 98)
29.Medical treatment of renal stones ( feb 98, mar 04)
30.Renal glomerular function tests ( sep 97)
31.Medical treatment for prostatic hypertrophy ( sep 97)
32.Hemofiltration ( sep 96)
33.Status of dialysis and transplantation in ESRD (jun99)
34.Hypophosphetimic rickets (mar 03)
35.Present status of renal transplantation (sep 03)
36.asymptomatic abnormalities of urinary sediment (mar 04)
37.Urinary indices in ARF (mar 06, 09)
38.Early diagnosis of diabetic nephropathy (nov09)
39.Renal tuberculosis (jun 08, feb 98)
40.Lactic acidosis (sep 96)
41.Metabolic acidosis
42.ANCA associated renal diseases (oct 10)
43.Drug doses in CRF (nov10)
44.Hypocalcemia
45.Discuss ukpds and its implications (sep 03)
46.Hyponatremia (may 05oct12)
47.Approach to acid base disturbances ( may 00 )
48.Hyperkalemia profile and treatment (may 05)
49.Hematuria (may09,oct13)
50.Tetany ( nov 08)
51.Structure and function of nephrons with channels . Explain how medullary
hypertonicity is achieved (oct13,12)
52.Hypophosphatemia(apr13)
53.Haemolytic uremic syndrome(apr13)
54.Approach to ARF (apr13)
55.Approach to acute nephritic syndrome (oct12)
56.Dermatological manifestations of CKD (oct12)
57.Calcium channel disorder of muscle paralysis (oct12)
 HEMATOLOGY AND ONCOLOGY
1. Describe iron metabolism ( apr 10)
2. Diagnosis and management of thalessimias (apr 10)
3. Prognostic scoring system in myelodisplastic syndromes ( apr 10)
4. Imitinib mesylate (apr 10)
5. Genetics of haemolytic anemias (apr 10)
6. Management of myelodysplastic syndromes ( nov 09)
7. Myelodysplastic syndromes ( may 09, jul94, mar 04)
8. Disseminated intravascular coagulation(may 09)
9. Bone marrow transplantation ( apr 12, jun 08, mar 04, jun 99)
10.Paraneoplastic syndromes (apr 09, nov 06)
11.Anti tumour antibodies ( apr 11)
12.Absorption of cyanocobalamine( feb 98)
13.Transfusion transmitted diseases ( may 06)
14.Prevention of cancer ( may 06)
15.Discuss the molecular biology, clinical features, and management of sickle
cell anemia ( sep 96, 02, nov 09)
16.Sideroblastic anemias (nov 09)
17.Acquired haemolytic anemias ( june 05)
18.Tumour lysis syndrome ( jun 08, may 09, mar 03)
19.Refractory anemias ( nov 06)
20.Multiple myeloma (apr13, nov 06, may 05)
21.Transfusion reactions ( nov 06)
22.Sickle cell syndromes ( nov 07, mar 04, june 99, sep 03)
23.Para-neoplastic neurological syndromes ( nov 09)
24.Principles of combination therapy in cancer management ( sep 03)
25.Discuss principles of cancer chemotherapy ( jun99, sep 03, jan 99)
26.Peripheral smear in anemia ( nov 06)
27.Tumour markers ( nov 06)
28.Thrombocytopenia ( may 06)
29.Oncogene ( may 05, jun99,, nov 08)
30.G-6 PD deficiency (may 05)
31.Short notes on neoangiogenesis( may 05)
32.Apoptosis ( may 05)
33.Management of CHRONIC MYELOID LEUKEMIA( may 05, apr 11)
34.Artificial blood (may 05)
35.Write in detail humoral manifestation of cancer ( sep 97)
36.FAB classification of AML (sep 04)
37.Hematopoietic growth factor for therapeutic use( may 00)
38.Hairy cell leukemia ( aug 98)
39.Erythropoietin ( aug 98)
40.Clinical application of hemorrheology ( mar 04)
41.POEMS syndrome ( sep 03)
42.Host versus graft diseases ( mar 04)
43.Polycythemia ( sep 97)
44.Hyperviscosity syndrome ( sep 96)
45.Glycoprotein 2b, 2c antagonists (sep 04)
46.Cancer drugs and vomitings ( sep 02)
47.Approach to a patient with anemia (nov 11)
48.Haemophilia
49.Biochemistry of homocysteine. What is its role in diseases ( sep 02)
50.Aplastic anemia(apr13)
51.Pancytopenia (oct13)
52.Sickle crisis and problems of hemoglobinopathies in india (oct13)
 POISONING, DRUG OVERDOSE AND
ENVENOMATION
1. Paracetamol poisoning (apr 12)
2. Management of cyanide poisoning (apr 10)
3. Organophosphorous poisoning (nov 10, jun 03, sep 03)
4. Poisonous snake bites (nov 07, may 00)
5. Acid base changes in salicylate poisoning ( sep 02)
6. Pupils in various poisonings (sep 97)
7. Snake bite management ( may 06)
8. Scorpion bite (may 05)
9. Neurotoxic snake envenomation ( sep 04)
10.Describe the clinical features , complications, and management of
insecticide poisoning (mar04, jun99)
11.Aluminium phosphide poisoning (jan99)
12.Intermediate syndrome(nov 08)
13.Epidemic dropsy(nov00, nov 09, may 00)
14.Acute poisoning principles of management( apr 11)
15.Endemic fluorosis (apr10)
16.Lathyrism (aug 98, may 05, mar 04)
17.Fluorosis (jun 08, may 06)
18.Hemotoxic snake bites and its management in india(oct13)
19.Copper sulphate poisoning(apr13)
20.Endo sulfan poisoning (oct12)
 MISCELLANEOUS
1. Heat stroke ( apr 12,oct12, nov10, may 05, sep 04, mar 04, jan 99, jun 99)
2. Peduncular hallucinosis(apr 10)
3. Radiation bio terrorism( may09)
4. Holistic medicine ( may 09)
5. Breaking bad news – P SPIKE approach( may 09)
6. Principles of end care medicine (may 09,apr13)
7. Bioterrorism ( nov 10)
8. Evidence based medicine (nov 10,08, )
9. Apoptosis (apr 11)
10.Meta analysis (nov 10)
11.Tele medicine (may 06)
12.Indications and limitations of MRI ( may 05)
13.Write short notes on fructose amine ( sep 02)
14.Helical computerised scan( sep 02)
15.Endothelium derived relaxing factor ( jun 99)
16.Cadaver transplantation ( feb 98)
17.Positron emission tomography (sep 97)
18.Polymerase chain reaction ( sep 97)
19.Electrocution (sep 97)
20.Discuss the role of free radicals in pathogenesis of diseases and its
therapeutic implications ( jan 99)
21.Algodystrophy ( jan 95)
22.Angiogenesis ( sep 03)
23.Chylohematuria (jul 94)
24. Physician assisted suicide ( apr 11)
25.Smoking cessation newer strategies (nov 10)
26.Adverse drug reactions (nov 10)
27.Prescribing in elderly (2010, sep 03, jan 99)
28.Principles of palliative care ( 2010)
29.Clinical ethics in practice of medicine (may 05)
30.Medical disorders during pregnancy ( nov 08)
31.Healthy ageing ( nov 08)
32.Approach to a patient with fever and rash (nov 08)
33.Approach to low back ache ( nov 08)
34.Pain management (*may 05)
35.Jet log disorders (apr13)
36.Heat exhaustion(apr13)
37.Pharmacokinetics and pharmacodynamics-its relevance in clinical practice
(apr13)
38.Health needs and challenges in india(oct13)

DERMATOLOGY

1. Urticaria (may 09, 05)

2. Cutaneous markers of systemic diseases ( jun 08)
3. Papulo-squamous skin diseases ( may 06)
4. Psoriasis (sep 07)
5. Vitiligo (feb 98)
6. Norwegian scabies (jun08)
7.
 DRUGS
1. LMWH (nov 06)
2. Acetyl cholinesterase (nov 06)
3. Lithium (nov 06, feb 98, mar 04)
4. Phosphodiesterase inhibitors ( may 07)
5. Which which cross placenta. Which drugs are secreted in human milk. Write
on teratogenicity of drugs ( feb 98)
6. Prostaglandins ( sep 96)
7. Anti-d (rh) Ig (sep96)
8. Drugs and Olympics (mar 04)
9. 5ht receptor modulators ( sep 03)
10.Angiotensin 2 receptor antagonists ( sep 03)
11.Melatonin ( sep 02)
12.COX-2 inhibitors ( mar 03)
13.Long acting BETA agonists.(sep 02)
14.Colony stimulating factor ( sep 03)
15.SSRI (may 04)
16.Antiplatelet drug resistance (nov 08)
17.Calcium channel blockers( nov 09)
18.Statins (may 09)
19.Atypical anti- psychotic drugs (may 09)
20.Abciximab (nov 09)
21.Endothelin receptor antagonists(apr13)
22.Drug induced musculoskeletal disorders (apr13)
23.Anti-amoebic drugs (oct12)
24.Pegylated interferon (oct12)
IMMUNOOGY AND RHEUMATOLOGY

1. Clinical features of sarcoidosis (apr 10)

2. Scleroderma renal crisis ( apr 10)
3. Hypouricaemic agents (apr 10)
4. Psoriatic arthritis ( apr 10)
5. Auto antibodies in systemic lupus erythmatosis (apr 10)
6. Wegner’s granulomatosis (apr 10, nov09)
7. Diagnosis and management of SLE (oct13, apr 09, may09,apr13)
8. Fibromyalgia syndrome (apr 09)
9. Approach to a patient with poly arthritis (apr 12)
10.Antiphospho lipid antibody syndrome ( apr 11, jun 08, jan99, sep03)
11.Extra articular manifestations of RA (jun 08, may 05)
12. Sjogren’s syndrome (nov 06, jan 95)
13.Mixed connective tissue disorders ( may 07)
14.Cytokines (may 07)
15.Sarcoidosis ( may07, sep 03)
16.Systemic sclerosis ( nov 07)
17.Gout (nov 07)
18.Anti nuclear antibodies ( mar 04)
19.Rheumatoid factor ( sep 03)
20.Asymptomatic hyperuricaemia (sep 03)
21.Synovial fluid analysis ( may 07)
22.ANCA (nov 06)
23.Auto antibodies ( may 06)
24.HLA-B27 (may 06)
25.Interferons (may 06, 00)
26.Lupus anticoagulants (may 05)
27.Anaphylaxis (may 05)
28.Hypertrophic osteoarthropathy (sep 09, jun 99)
29.Explain the features of mixed connective tissue diseases. Outline the
management of a case ( jul 94)
30.Immunomodulation (jul 94)
31.Describe the clinical features, diagnosis, management of systemic
sclerosis. (sep 96)
32.Side effects of drugs used in RA ( sep 97)
33.DMARD (jan99, may05, jun99,sep02)
34.Fibromyalgia (mar04, jun99,may09)
35.What are crystal arthropathies. Write the clinical features and
management of GOUT (mar 03, may05)
36.Hand in RA (may 06)
37.Criteria for diagnosis of RA (sep 04)
38.Cytokine manipulation in RA (mar 04)
39.Bisphosphonates (may05)
40.Reactive arthritis ( sep 03, 02)
41.Newer drugs in RA (nov 09)
42.Diagnosis in RA (nov 08)
43.Compliment system (sep 04)
44.Apoptosis (may 05)
45.CD4-T cells (may00)
46.Mediators of inflammatory injury ( aug 98)
47.Drug induced lupus (mar 04)
48.Toll like receptors (nov 09)
49.Current treatment of rheumatic arthritis(nov10)
50.Pathophysiology of fibrosing alveolitis (nov 09)
51.Hypersensitive vasculitis(oct13)
52.Criteria for rheumatic fever and rheumatic heart disease(apr13)
53.Osteoarthritis (apr13)
54.Management of RA(apr13)
55.Microvascular thrombotic crisis in SLE (oct12)
56.Fibromyalgia (oct12)
 CRITICAL CARE MEDICINE
1. Tumour lysis syndrome ( may09)
2. Approach to a patient in shock (apr 11)
3. Activated protein C in management of severe sepsis(apr 11)
4. Sudden cardiac death (apr11, nov 7)
5. Advanced cardiac life support ( jun 08)
6. Multi-organ dysfunction syndrome (sep03)
7. Sepsis pathophysiology (sep 03)
8. ARDS ( nov 08)
9. SIRS (may 09,oct12)
10.Oncologic emergency
11.Neutropinic enterocolitis(apr13)
12.Tumour lysis syndrome (oct13)
 CENTRAL NERVOUS SYSTEM
1. Approach to a patient with stroke (apr 12)
2. Management of parkinsonism (apr13,apr12,nov 06,)
3. Newer drugs used as neuro protective therapy in parkinsonism (apr 10)
4. Immunotherapy of myasthenia gravis (apr 10)
5. Mono neuritis multiplex (nov09)
6. Usefulness of chest imaging in the evaluation of gait ataxias (nov09)
7. Role of EEG in epilepsy (may09)
8. Hereditary ataxia (may 09)
9. Atypical anti-psycotic drugs (may09)
10.Alcohol withdrawal (may 09)
11.Insomnia (may09)
12.Limbic system (apr11)
13.Nerve conduction velocity (apr11)
14.Management of refractory epilepsy (apr11)
15.Cluster headache (may07,05, sep04)
16.Aphasia (nov06)
17.Approach to low backache (nov 08)
18.Syncope (nov 08)
19.Basillary migraine (nov09,oct13)
20.Ring lesions in computerised brain scan (jun08)
21.Alzheimers disease (jun 08, sep03)
22.Prions (jun08)
23.Viral meningitis (jun08)
24. Neurocutaneous markers (nov 06)
25.Management of status epilepticus (nov 06)
26.Neuro-cystesarcosis (nov 06,may05)
27.Chronic fatigue syndrome (may 07)
28.Cerebellar abscess (may 07)
29.Anxiolytic drugs (may07)
30.CT SCAN in stroke (nov 07)
31.Acute inflammatory demyelinating polyneuropathy (nov07)
32.Nicotine deaddiction (nov 07)
33.Cerebral edema pathogenesis and management (mar04,may05)
34.Draw a transverse section of spinal cord at T10 level (may 04)
35.Discuss electrophysiological studies in neuromuscular disease (mar 04)
36.Anatomy of cavernous sinus and clinical picture of cavernous sinus
thrombosis(sep 03)
37.Neurotransmitters (sep03,may07,jan99.oct12)
38.Write the anatomy of optic nerve , draw visual field carts that occur in
various neurological states (mar03)
39.Anatomy of optc nerve and localisation of lesions at various levels (sep 02)
40.Circle of willis(may 07)
41.CSF analysis (nav 06)
42.SSRI (may 06, aug 98)
43.Electromyography (may06)
44.Nerve supply of urinary bladder and neurogenic bladder (sep 04)
45.Catecholamine-o-methyltransferase inhibitors (may05)
46.Describe the relation tributaries and connections of the cavernous sinus and
discuss their clinical significance (sep 96)
47.Antiepileptic drugs (jul94)
48.Discuss craniovertebral anamolies (jan 95)
49.Anatomy and physiology of cerebral circulation. What are the strokes?
Manifestations and complications of SAH, diagnosis and management. (Jan
95)
50.Periodic paralysis (may06)
51.Anti-psycotic drugs (may06)
52.Asburg’s criteris for acute inflammatory demyelinating polyneuropathy(may
05)
53.Risk factors for stroke (may05)
54.Iatrogenic neuromuscular diseases (sep04)
55.Short notes on thrombolysis in stroke (sep03)
56.What are the slow virus infection of CNS describe the epidemiology,
etiology, pathology, clinical features, diagnosis, course, prognosis, and
treatment of multiple sclerosis (jan 95)
57.Short notes on cortical vein thrombosis (jul 95)
58.Neuroleptic induced acute dystonic reaction(sep 96)
59.Diagnosis of nyaesthenia gravis (may06)
60.Psychotherapy (may06)
61.Electro convulsive therapy (sep04, jan99)
62.AIDP (sep 04)
63.Anti depressant drugs (mar04, sep97)
64.Discuss current trends in management of CVA (jan 99)
65.Classify seizure disorders. Discuss principles of management (aug 98)
66.Classify epilepsy. What are the drugs used in seizure disorders. Outline their
toxicity (feb 98)
67.Cerebellar hematoma (feb 98)
68.Write the etiology, clinical features, diagnosis, and management of subdural
hematoma and hygroma (sep 97)
69.Hemifacial spasm (sep 96)
70.Normal pressure hydrocephalous (jul94)
71.Endocrine myopathies (jul 94)
72.First seizure management (may 04)
73.Viral encephalitis (mar04)
74.Motor neuron diasese in tropics(mar04)
75.Febrile fits (sep 02)
76.Vascular supply of cerebellum (nov09)
77.Diagnosis of viral infections of nervous system (nov09)
78.Genetics of muscular dystrophies (nov09)
79.TIA (nov08)
80.Dymentia (nov08,oct12)
81.Choice of AED (nov 08)
82.WELLENBERG syndrome (nov09)
83.Discuss sleep disorders (nov11)
84.Recent advances in management of parkinson’s disease (nov10)
85.Treatment of peripheral neuropathy (2010)
86.Neutrophic markers (apr13)
87.Approach to chorea pathogenesis (apr13)
88.Anterior circulation infarct (apr13)
89.Depression in medical disorders(apr13)
90.Tropical spastic paraplegia (apr13)
91.Cerebral circulation and its relevance in neurological localisation (oct13)
92.Evaluation of a patient with dizziness / vertigo (oct13)
93.Cerebral vein thrombosis- diagnosis and management (oct13)
94.Newer anti-epileptic drugs (oct13)
95.Deliberate self harm. The problem and causes in india(oct13)
96.Posterior circulation infarct (oct12)
97.Management of multiple sclerosis (oct12)
 INFECTIONS
1. Diagnosis of bacterial endocarditis (apr12)
2. Laboratory diagnosis of cholera (apr10)
3. Hospital acquired infections (may09,aug 98)
4. Botulin toxin (may09)
5. Reactions in leprosy (may 09,apr13)
6. Leptospirosis (may09,05,mar04,sep03,mar03,nov11)
7. Management of infective endocarditis (nov11,may..)
8. MDR TB(nov11,may07,sep03,04,oct13)
9. Reactional states in leprosy (nov11)
10.Anti malarial combinations (nov 11)
11.Botulinum toxin. Theurapeutic uses (nov11,sep03)
12.Viral hemorrhaegic fever (nov11,may07)
13.Immunological tests in diagnosis of TB(apr11)
14.Immune reconstitution syndrome (apr11)
15.Treatment of lepromatous leprosy (jun08)
16.Bubonic plague (jun08, may 0…)
17.Giardiasis (jun08)
18.Diarrhoea in HIV (nov 06)
19.Management of enteric fever (nov06)
20. MALARIA (nov06,sep03,nov08,may07,ocy13)
21.Dengue (nov06,aug 98,sep03,oct13)
22.Amoebiasis (nov06,mar04,may00,)
23.Serology syphilis (nov06)
24.Radiology in aspergillosis (may07)
25.Filariasis (may07)
26.Pneumocystis carnii (may07,04, feb98,mar04)
27.Secondary syphilis (may07)
28.Cholera (may07)
29.Legionella infection (nov07)
30.Non tuberculosis mycobacteria (nov07)
31.Chloroquine resistant malaria (jan99,may07, 05, sep04)
32.Amino-glycosides (mar04)
33.Anti retroviral therapy (mar04)
34.Cephalic tetanus (mar04)
35.Beta lactams (sep03)
36.Newer quinolones (nov06)
37.Lab diagnosis of anthrax (may05)
38.Artemesinin and derivatives (may00, sep02)
39.Chlamidia pneumonia (sep96)
40.Anti-viral drugs (jan95)
41.Duke criteria for infective endocarditis (may06)
42.Post exposure prophylaxis for hiv infection(may06,mar04)
43.Neutropinic fever (mar04)
44.Probiotics (mar04)
45.HACEK group organisms (may00)
46.Describe the neurological manifestations of HIV infections (mar04,feb
98)
47.Local tetanus (jul94)
48.Clinical spectrum of arbo virus infection in india (nov09)
49.Prophylaxis against rabies (nov09)
50.Indications of antiretroviral therapy in HIV infections (sep03,may06)
51.TB and HIV infections (sep04)
52.Clinical clues suggestive of legionnaires disease(sep 04)
53.Opportunistic infections (may05,sep03)
54.Tropical pulmonary eosinophilia (may 06,00,05, nov08,)
55.Treatment schedules for leprosy (may06,mar04)
56.Malaria vaccine present status (may06)
57.Rabies post exposure prophylaxis (nov05, may06,sep03)
58.Tetanus (may05, mar03,apr13)
59.DOTS (may05,sep04)
60.Anthrax (sep 04,nov 09)
61.Toxic shock syndrome (sep04)
62.Ulcerative genital lesion (sep04)
63.HIV vaccine. Its current status (mar04)
64.Type 2 lepra reaction (sep03)
65.RNTCP (sep03)
66.Drug resistant salmonella (sep03)
67.Write short notes on a)cancrum oris b)ivermectin c)Marburg ebola
disease d)trichinella spiralis (mar03)
68.Write short notes on granuloma inguinale (sep02)
69.Leprosy vaccine (jun99)
70.Cerebral malaria (jan99)
71.Classification system for HIV (jan99)
72.Lab diagnosis of TB (jan99)
73.PUO (aug98)
74.Reactions in leprosy (aug98,jan95)
75.Immunisation in adult (aug98)
76.Plague (aug98)
77.Clinical features of toxoplasmosis (nov09)
78.Management of visceral leishmaniasis (nov09)
79.Strongyloides hyperinfestations (nov09)
80.Immunological aberrations in leprosy(nov09)
81.Podoconiosis (non filarial elephantiasis)(feb98)
82.Bartonellosis (feb98)
83.Write in detail clinical features and management of GUT protozoa
(sep97)
84.Babesiosis (sep97)
85.Leech infestations (sep97)
86.Respiratory virus (sep 97)
87.Myiasis (sep97)
88.Strongyloidosis (sep96)
89.Creeping eruption (sep96)
90.Chyluria (sep96)
91.Needle stick malaria (sep96)
92.Hydatid disease (jan95)
93.Praziquantel (jan95)
94.Discuss the resistant malaria. What are the different clinical types of
falciparum malaria and how do you treat them (jan95)
95.Hymenolepis (jul94)
96.Multidrug therapy in leprosy (jul94)
97.Leprosy (sep97,nov08)
98.Pyoderma (may05)
99.Tropical spastic paraplegia (nov09)
100. Opportunistic infection in AIDS(nov08)
101. Acute viral syndrome in HIV
102. IRIS
103. Clinical features of toxoplasmosis (nov09)
104. Invasive pulmonary aspergillosis (nov09)
105. Acute HIV syndrome (apr11)
106. Drug treatment of chronic hep B(Apr11)
107. Complications of salmonellosis (apr11)
108. Modified WHO multidrug therapy of leprosy (apr11)
109. Lathyrism (apr11)
110. Prophylaxis of viral hepatitis(apr11)
111. Cutaneous leishmaniasis (apr10)
112. Cholera toxins and their mechanism of action(apr10)
113. Malaria vaccines (apr10)
114. Clinical features of weil’s disease (apr10)
115. Management of listerosis (apr10)
116. Viral opportunistic infections in AIDS(pr10)
117. Staphylococcal toxin mediated disease(apr10)
118. Pulmonary manifestations of parasitic infections (apr10)
119. Diagnosis and Management of Kala Azar(oct13)
120. Large bowel diarrhoeas diagnosis and management(oct13)
121. H1n1 vaccine (apr13)
122. Approach to fever with jaundice (apr13)
123. Pernicious malaria (apr13)
124. Viral markers in hepatits B(apr13)
125. Tropical splenomegaly (oct12)
126. Fever with rash (oct12)
127. Botulinum (oct12)
128. Adult vaccines (oct12)